Hot Investor Mandate: US Private Investment Firm Invests in Digital Health and Medical Technologies with Software Component, Prefers Founding Team with Both Technical and Business Expertise

9 Nov

An early-stage private investment firm is based in Silicon Valley, CA. The initial investments are typically $25,000-$100,000 and the firm can scale investments from there. The firm also provides select startups with business development support through a no-fee program. The firm will consider investing in companies worldwide.

The firm is interested in investing in digital health and medical technology and invests in subsectors in which the firm and its industry partners can apply expertise; within medical devices, typically this means products that have a significant software component, including biosensors, wearables, and health monitoring devices. Within digital health, the firm’s  interests include: Care Management, Hospital Workflow, Diagnostics, A.I. & Big Data, Population Health, and Patient Adherence. The firm prefers B2B business models.

The firm prefers to invest in companies with at least two co-founders, one with technical expertise and one with business expertise. In addition to due diligence on the management team and technology, the firm also considers a product’s potential market opportunity.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

Important Deadlines Are Approaching

2 Nov

By Cameron Hurlburt, Manager of Business Development – West Coast (US), LSN

It is officially November and some key deadlines for attending Life Science Nation (LSN) ‘s flagship RESI conference, in January of the new year, RESI JPM, are approaching. LSN wants to make sure our community takes advantage of the opportunities to save, pitch, and prepare for partnering meetings to start 2024 on the right track. Mark your calendars:

1. Price Increase on November 17

Register by November 17 and save $300 with early bird rates. Join RESI JPM 2024 – the largest early-stage life sciences partnering event of the year at Marine’s Memorial Club & Hotel in San Francisco on January 9 during the annual JPM healthcare conference week. If you are fundraising, this is your chance to make compelling connections and kickstart fundraising campaign.

Register-now-button-new

2. Innovator’s Pitch Challenge Deadline is November 22

The application deadline to apply is November 22. The Innovator’s Pitch Challenge (IPC) is an opportunity for early-stage life science and healthcare companies to gain additional exposure to conference attendees and pitch directly to a panel of judges, featuring active investors and industry experts. The slots are filled on a first come, first served basis so we highly encourage early application submissions!

3. Partnering Launches on December 4

Registering for RESI JPM early ensures you will be among the first attendees to access the RESI Partnering System. The RESI Partnering Platform helps you find non-traditional partners from the newest sources of capital, including family offices, foundations, academic institutions, philanthropic organizations, and some of the hottest emerging biotech and medtech companies worldwide. If you are looking to take your partnering to the next level, consider adding the premier package to increase your access to investor profiles ($500). Premier partnering grants you access to investor mandates in the LSN Investor Database, which includes direct emails to support your target list and facilitate year-round connection.

 WHAT TO EXPECT AT RESI JPM 2024

LSN will host 500+ early-stage life Science investors and strategic partners, 500+ early-stage life science start-ups & fundraising executives, and 200+ service providers including CROs/CMOs, Tech Hubs, and Regional Organizations.

There are 100+ partnering meeting slots per attendee during the 3-day hybrid conference with additional ad-hoc meeting opportunities. Registered in-person attendees have access to    14+ Investor Panels, Workshops, and Entrepreneurial Education Classes and 50+ In-person Pitch Slots with 14 Pitch Sessions in RESI Innovator’s Pitch Challenge

Have any questions? Feel free to contact us!

RESI-SF-2024-Banner-1100

Medical Device Panel at RESI JPM 2024

2 Nov

By Joey Wong, Senior Investor Research Analyst, Hong Kong BD, LSN

The panel recruitment for RESI JPM, taking place in-person on January 9, 2024, has exceeded our expectations, and we are happy to announce the full lineup of the Medical Devices Investors Panel. This popular RESI panel will host an insightful conversation on forward-looking trends in medical device innovations. The participating panelists are a diverse and international representation of speakers at this RESI. By bringing together active investors and strategics with various backgrounds, RESI aims to bridge the gap between investors and fundraising entrepreneurs, fostering a platform for open communications between the buy side and sell side.

Final - Medical Devices Panel JPM24

In addition to the Medical Device Panel, LSN’s investor research team has curated a program of panels, covering a wide range of topics highly relevant to early-stage life science and healthcare innovators. Each panel will feature active investors and key strategic partners to share their knowledge based on extensive industry experiences.

Some of the panels will explore various sectors of interest, such as therapeutics, or emerging areas like mental and behavioral health. Speakers will discuss their insights on the investment landscape, future trends, and opportunities specific to these sectors or indication areas. Other panels are geared towards distinct types of industry players or investment groups that play an important strategic role in the ecosystem, such as large pharmaceutical companies, health system partners, and cross-border investment groups. These panels will delve into the strategic roles these organizations play within the ecosystem, what they are looking for in the sector, things to consider, and how companies can partner with groups like themselves.
RESI-SF-2024-Banner-1100

RESI 2024 Series Media Partnership Opportunities

2 Nov

By Caitlin Dolegowski, Marketing Manager, LSN

We’d like to introduce partnering opportunities with  Life Science Nation (LSN)’s Redefining Early Stage Investments (RESI) in 2024.

LSN’s partnering conference series is the biggest in North America focusing on early-stage life science investments and strategic partnerships. We are expecting 700-1,200 attendees to participate from 5 continents.

As a media partner, you would promote and advertise LSN partnering conferences through your communication channels, and in return, LSN offers:

  • Logo featured on LSN’s Next Phase Newsletter (45,000+ readership), Tech Hub Monthly Newsletter (5,000+ readership), event websites, event program guide, and onsite signs as a media partner.
  • Quarter page ad in RESI program guide during 2024 series.
  • Unique discount code for your constituents ($100 off registration).
  • Receive a complimentary RESI pass and an additional free ticket if there are at least two (2) registrations using the discount code.
  • Two (2) posts to LSN’s LinkedIn network with the content of the partner’s choice.
  • Banner ad featured for three (3) months on Next Phase newsletters. – content provided by the company.

Media partnership isn’t just a promotional tool for publicity and customer loyalty, it can also be expected to generate goodwill and awareness at the RESI conference series. LSN makes media sponsorship as convenient as possible, connecting your constituents with valuable resources. Here are a few examples:

  • Include the LSN logo on your conference website(s) as a media partner.
  • Include the RESI conference with a unique discount on your event calendar.
  • Two (2) email blasts to your network promoting RESI conferences or Two (2) posts to your LinkedIn (or similar social media) network with content provided by LSN.
  • Banner ad featured for three (3) months of your publication newsletter with content provided by LSN.

Thank you for your consideration. If you have any questions or want to start the media partnership today, please contact Caitlin Dolegowski, Marketing Manager at Life Science Nation.

RESI-SF-2024-Banner-1100

Hot Investor Mandate: VC Firm in Japan Invests Up to $10M in Early-Stage Life Science Companies Across the Globe, Open to All Therapeutic Modalities

2 Nov

A venture capital firm in Japan invests in life science, biotech, IT and software, and agriculture. Currently, the firm manages two funds: one fund which funds later stage companies, and another fund which is an open innovation fund to support the creation of companies and early-stage startups. The firm will also support company creation and sales in Japan as well as overseas. In total, the firm has about $400M to invest from, with $5M-10M as a typical check size per round and the same amount reserved for future follow-on investments. The firm is open to investing in all financial rounds and all sectors of life science and biotech. The firm invests globally.

The firm invests in all sectors of life science and biotech including, but not limited to, therapeutics, diagnostics, medical devices, digital health, etc. across all stages of development, focusing on early stage. Within therapeutics, the firm is open to investing in all modalities including novel biologics (i.e. cell & gene therapy). The firm is also open to all indications including orphan diseases.

The firm does not have specific management team requirements, however the firm will take a board or observer seat. The firm is open to acting as either a lead or co-investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

Hot Investor Mandate: Corporate Venture Arm of Major Corporation Invests in Therapeutics, Digital Health, and AI Applications Through Multiple Funds

2 Nov

A venture capital arm of a global conglomerate has several global offices including two sites in the US. In 2021, the firm raised a dedicated life science fund to invest in therapeutic and bioprocessing companies with flexibility of entering at different stages of development. The investment size varies depending on the opportunity. The firm is actively seeking new investment opportunities globally.

The firm will make new investments from both traditional funds and their new life science fund. The traditional funds invest in customer-centered health strategies, which may include mobile health IT, digital health, and artificial intelligence applied to healthcare. The new life science fund is interested in therapeutics, particularly gene therapy, ADC technologies, RNA delivery platform technologies, and bioprocessing business that support these strategic areas of interest.

The firm primarily invests in life science companies with a strong and experienced management team. The firm usually takes a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

Hot Investor Mandate: VC Invests in Series A and B Rounds in Life Science Technologies With Opportunistic Mandate, Focusing on USA-Based Companies

2 Nov

A venture capital firm founded in 2012 and headquartered in the US invests in life science, tech, and healthcare companies at Series A and B stages. The firm requires their portfolio companies to have at least one woman in the founding team. Typical check size is USD $1M-3M. The firm is open to investing in global companies, however, the companies need to have some presence in the U.S. as well. The firm usually acts as a co-investor.

The firm’s premise is frontier technology and medical breakthrough. The firm invests in a wide range of life science sectors including therapeutics, diagnostics, and digital health. The firm has invested in hardware, AI in drug discovery, gene editing, and more. The firm is indication-agnostic and will look at companies in all stages of development, though most are earlier.

The firm requires portfolio companies to have at least one woman on the founding team. The firm may not take a board seat on a case-by-case basis as the firm likes to maintain strong relationships with founders and advise in an informal setting.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.